期刊文献+

影响慢性肾脏病患者血清甲状旁腺素的相关因素分析

Analysis of Related Factors Affecting Serum Parathyroid Hormone in Chronic Kidney Disease
下载PDF
导出
摘要 目的:甲状旁腺激素(parathyroid hormone, PTH),是甲状旁腺主细胞分泌的碱性单链多肽类激素,在慢性肾病的并发症发病中日益显示其重要性。通过检测本肾病中心599例慢性肾病患者的PTH值,探讨不同阶段的慢性肾病PTH异常率的差异,并分析性别和年龄是否影响慢性肾病患者的PTH值。方法:利用化学发光免疫夹心法检测PTH浓度。结果:统计结果显示尿毒症患者组的PTH异常率显著高于非尿毒症患者组(P = 0.02);男性尿毒症患者的PTH异常率明显高于女性尿毒症患者(P = 0.007);尤其值得注意的是,无论是尿毒症组还是非尿毒症组,年龄 ≥ 50的慢性肾病患者PTH异常率比年龄 <50的患者低,且在非尿毒症组具有显著性差异(P = 0.006)。结论:PTH异常与慢性肾脏病的恶化明显相关,年龄因素参与慢性肾病患者PTH调控的机理有待进一步阐明。 Objective: Parathyroid hormone (PTH), is a basic single chain polypeptide hormone secreted by parathyroid cells, has become increasingly important in the pathogenesis of chronic kidney disease. By testing the PTH value of 599 patients with chronic kidney disease (CKD), we investigate the dif-ference of PTH abnormal rate in different stages of chronic kidney disease, and analyze whether the gender and age affect the PTH value of patients with chronic kidney disease. Methods: The concen-tration of PTH was detected by chemiluminescence immunoassay. Results: Statistical results showed that the abnormal rate of PTH in uremic patients was significantly higher than that in non-uremic patients (P = 0.02). The abnormal rate of PTH in male uremic patients was significantly higher than that in female patients with uremia (P = 0.007). In particular, it was worth noting that, in both uremic group and non-uremic group, the PTH abnormal rate of the CKD patients aged ≥50 was lower than that of age
出处 《临床医学进展》 2016年第4期231-234,共4页 Advances in Clinical Medicine
  • 相关文献

参考文献5

二级参考文献45

  • 1王成,娄探奇,唐骅,陈珠江,石成钢,尹培达,余学清.常用血液净化方法对维持性血液透析患者血清甲状旁腺素的清除效果[J].中华急诊医学杂志,2005,14(1):61-63. 被引量:108
  • 2Wetmore JB,Quades LD.Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease:time for a paradigm shift? Nat Clin Pract Nephrol,2009,5:24-33.
  • 3Liu S,Quarles LD.How fibroblast growth factor 23 works.J Am Soc Nephrol,2007,18(6):1637-1647.
  • 4Kuro-o M.Klotho in chronic kidney disease--what' s new?Nephrol Dial Transplant,2009,24(6):1705-1708.
  • 5Ketteler M,Biggar PH.As nature did not predict dialysis-what we can learn from FGF23 in end-stage renal disease? Nephrol Dial Transplant,2009,24(9):2618-2620.
  • 6Martin KI,Goldfarb S.Renal bone disease,disorders of divalent ions and nephrolithiasis NephSAP,2008,7:304-317.
  • 7Valle C,Rodriguez M,Santarnaria R,et al.Cinacalcet reduces the set point of the PTH-calcium curve.J Am Soc Nephrol,2008,19(12):2430-2436.
  • 8Messa P,Macário F,Yaqoob M,et al.The OPTIMA study:assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.Clin J Am Soc Nephrol,2008,3(1):36-45.
  • 9Fishbane S,Shapiro WB,Corry DB,et al.Cinacalcet HCI and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidisrn in dialysis patients compared with vitamin D alone:the ACHIEVE study results.Clin J Am Soc Nephrol,2008,3(6):1718-1725.
  • 10Strippoli GF,Palmer S,Tong A,et al.Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.Am J Kidney Dis,2006,47(5):715-726.

共引文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部